Keros Therapeutics, Inc.
KROS
$10.10
-$0.56-5.25%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.01M | 33.18M | 244.06M | 246.72M | 232.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.01M | 33.18M | 244.06M | 246.72M | 232.84M |
| Cost of Revenue | 75.76M | 96.93M | 129.54M | 157.36M | 187.07M |
| Gross Profit | -60.75M | -63.75M | 114.52M | 89.36M | 45.78M |
| SG&A Expenses | 40.62M | 46.50M | 46.85M | 45.77M | 45.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 116.38M | 143.43M | 176.39M | 203.13M | 232.53M |
| Operating Income | -101.37M | -110.25M | 67.67M | 43.59M | 312.00K |
| Income Before Tax | -86.10M | -90.31M | 91.90M | 71.15M | 26.89M |
| Income Tax Expenses | -2.94M | -5.16M | 4.88M | 6.70M | 8.12M |
| Earnings from Continuing Operations | -83.16 | -85.15 | 87.01 | 64.45 | 18.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.16M | -85.15M | 87.01M | 64.45M | 18.77M |
| EBIT | -101.37M | -110.25M | 67.67M | 43.59M | 312.00K |
| EBITDA | -99.77M | -108.68M | 69.18M | 45.03M | 1.67M |
| EPS Basic | -3.70 | -3.01 | 1.86 | 1.58 | 0.35 |
| Normalized Basic EPS | -2.37 | -1.97 | 1.23 | 1.09 | 0.35 |
| EPS Diluted | -3.70 | -3.01 | 1.82 | 1.54 | 0.31 |
| Normalized Diluted EPS | -2.37 | -1.97 | 1.20 | 1.07 | 0.32 |
| Average Basic Shares Outstanding | 107.25M | 128.06M | 148.99M | 162.13M | 159.10M |
| Average Diluted Shares Outstanding | 107.25M | 128.06M | 149.46M | 162.60M | 159.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |